Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

NCT02322593 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02322593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02322593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
May 31, 2020
Enrollment
711 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer